Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse
NCT04998786Phase 2Active, not recruiting
- Sponsor
- CHU de Nantes
- Start
- Dec 2021
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide and ixazomib in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: Percentage of patients achieving very good partial response (VGPR) or better at 18 months. Started Dec 2021; status: active, not recruiting.
02
Drugs
iberdomideixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04998786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998786.